Terms: = Prostate cancer AND ERG, P11308, 2078 AND Prognosis
182 results:
1. Transcription Factors in prostate cancer: Insights for Disease Development and Diagnostic and Therapeutic Approaches.
Silva KCS; Tambwe N; Mahfouz DH; Wium M; Cacciatore S; Paccez JD; Zerbini LF
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674385
[TBL] [Abstract] [Full Text] [Related]
2. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract] [Full Text] [Related]
3. Loss of feedback regulation between FAM3B and androgen receptor driving prostate cancer progression.
Ma T; Jin L; Bai S; Liu Z; Wang S; Shen B; Cho Y; Cao S; Sun MJS; Fazli L; Zhang D; Wedderburn C; Zhang DY; Mugon G; Ungerleider N; Baddoo M; Zhang K; Schiavone LH; Burkhardt BR; Fan J; You Z; Flemington EK; Dong X; Dong Y
J Natl Cancer Inst; 2024 Mar; 116(3):421-433. PubMed ID: 37847647
[TBL] [Abstract] [Full Text] [Related]
4.
Boldrini L; Bardi M
Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628609
[TBL] [Abstract] [Full Text] [Related]
5. Investigation of Clinically Significant Molecular Aberrations in Patients with prostate cancer: Implications for Personalized Treatment, prognosis and Genetic Testing.
Fountzilas E; Kouspou M; Eliades A; Papadopoulou K; Bournakis E; Goussia A; Tsiatas M; Achilleos A; Tsangaras K; Billioud G; Loizides C; Lemesios C; Kypri E; Ioannides M; Koumbaris G; Levva S; Vakalopoulos I; Paliouras A; Pervana S; Koinis F; Bumci R; Christopoulou A; Meditskou S; Psyrri A; Boukovinas I; Visvikis A; Karavasilis V; Koukoulis GK; Kotsakis A; Giannakis D; Fountzilas G; Patsalis PC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511593
[TBL] [Abstract] [Full Text] [Related]
6. 'High proliferative cribriform prostate cancer' defines a patient subgroup with an inferior prognosis.
Bogaard M; Skotheim RI; Maltau AV; Kidd SG; Lothe RA; Axcrona K; Axcrona U
Histopathology; 2023 Dec; 83(6):853-869. PubMed ID: 37501635
[TBL] [Abstract] [Full Text] [Related]
7. Development and characterization of an ETV1 rabbit monoclonal antibody for the immunohistochemical detection of ETV1 expression in cancer tissue specimens.
Schafer C; Young D; Singh H; Jayakrishnan R; Banerjee S; Song Y; Dobi A; Petrovics G; Srivastava S; Srivastava S; Sesterhenn IA; Chesnut GT; Tan SH
J Immunol Methods; 2023 Jul; 518():113493. PubMed ID: 37196930
[TBL] [Abstract] [Full Text] [Related]
8. erg Status at the Margin Is Associated With Biochemical Recurrence After Radical prostatectomy With Positive Surgical Margins.
Salles DC; Mendes AA; Han M; Partin AW; Trock BJ; Jing Y; Lotan TL
Mod Pathol; 2023 Jul; 36(7):100147. PubMed ID: 36828362
[TBL] [Abstract] [Full Text] [Related]
9. Determination of TMPRSS2-erg, SPOP, FOXA1, and IDH1 prostate cancer molecular subtypes in Colombian patients and their possible implications for prognosis.
Montero-Ovalle W; Sanabria-Salas MC; Mesa-López de Mesa J; Varela-Ramírez R; Segura-Moreno YY; Sánchez-Villalobos SA; Nuñez-Lemus M; Serrano ML
Cell Biol Int; 2023 May; 47(5):1017-1030. PubMed ID: 36740223
[TBL] [Abstract] [Full Text] [Related]
10. Metabolic pathways enriched according to erg status are associated with biochemical recurrence in Hispanic/Latino patients with prostate cancer.
Acosta-Vega NL; Varela R; Mesa JA; Garai J; Baddoo MC; Gómez-Gutiérrez A; Serrano-Gómez SJ; Lemus MN; Serrano ML; Zabaleta J; Combita AL; Sanabria-Salas MC
Cancer Med; 2023 Feb; 12(4):4306-4320. PubMed ID: 36329628
[TBL] [Abstract] [Full Text] [Related]
11.
Kobelyatskaya AA; Kudryavtsev AA; Kudryavtseva AV; Snezhkina AV; Fedorova MS; Kalinin DV; Pavlov VS; Guvatova ZG; Naberezhnev PA; Nyushko KM; Alekseev BY; Krasnov GS; Bulavkina EV; Pudova EA
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232996
[TBL] [Abstract] [Full Text] [Related]
12. Differences in prostate cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different?
Zhou CD; Pettersson A; Plym A; Tyekucheva S; Penney KL; Sesso HD; Kantoff PW; Mucci LA; Stopsack KH
Cancer Prev Res (Phila); 2022 Dec; 15(12):815-825. PubMed ID: 36125434
[TBL] [Abstract] [Full Text] [Related]
13. [Epidemiological and clinicopathological characteristics of prostate cancer in Hunan].
Zou B; Long Y; Yang ZM; Gao RS; Lin QF; Dai XJ; Yi G; Wang QZ; Zhou Q; Zhang XB
Zhonghua Nan Ke Xue; 2022 Sep; 28(9):786-791. PubMed ID: 37839003
[TBL] [Abstract] [Full Text] [Related]
14. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
[TBL] [Abstract] [Full Text] [Related]
15. In situ expression of erg protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis.
Kidd SG; Bogaard M; Carm KT; Bakken AC; Maltau AMV; Løvf M; Lothe RA; Axcrona K; Axcrona U; Skotheim RI
Mol Oncol; 2022 Aug; 16(15):2810-2822. PubMed ID: 35574900
[TBL] [Abstract] [Full Text] [Related]
16. ARPC1B Is Associated with Lethal prostate cancer and Its Inhibition Decreases Cell Invasion and Migration In Vitro.
Gamallat Y; Zaaluk H; Kish EK; Abdelsalam R; Liosis K; Ghosh S; Bismar TA
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163398
[TBL] [Abstract] [Full Text] [Related]
17. Correlation of integrated erg/PTEN assessment with biochemical recurrence in prostate cancer.
Brady L; Carlsson J; Baird AM; Casey O; Vlajnic T; Murchan P; Cormican D; Costigan D; Gray S; Sheils O; O'Neill A; Watson RW; Andren O; Finn S
Cancer Treat Res Commun; 2021; 29():100451. PubMed ID: 34507017
[TBL] [Abstract] [Full Text] [Related]
18. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.
Liu D; Augello MA; Grbesa I; Prandi D; Liu Y; Shoag JE; Karnes RJ; Trock BJ; Klein EA; Den RB; Demichelis F; Davicioni E; Sboner A; Barbieri CE
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33998599
[TBL] [Abstract] [Full Text] [Related]
19. Clinicopathologic features of metastatic small cell carcinoma of the prostate to the liver: a series of four cases.
Bell PD; Huber AR; Agostini-Vulaj D
Diagn Pathol; 2021 Apr; 16(1):35. PubMed ID: 33892760
[TBL] [Abstract] [Full Text] [Related]
20. Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer.
Marx A; Koopmann L; Höflmayer D; Büscheck F; Hube-Magg C; Steurer S; Eichenauer T; Clauditz TS; Wilczak W; Simon R; Sauter G; Izbicki JR; Huland H; Heinzer H; Graefen M; Haese A; Schlomm T; Bernreuther C; Lebok P; Bonk S
Cancer Biol Med; 2021 Feb; 18(1):245-255. PubMed ID: 33628598
[TBL] [Abstract] [Full Text] [Related]
[Next]
